Research graph
References from A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in lung cancer cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Oncolytic viruses as therapeutic cancer vaccines
10.1186/1476-4598-12-103 · 2013 · External reference
Clinical Trials with Oncolytic Adenovirus in China
10.2174/156800907780058817 · External reference
The advent of oncolytic virotherapy in oncology: The Rigvir® story
10.1016/j.ejphar.2018.08.042 · 2018 · External reference
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
10.1245/s10434-018-6803-0 · 2018 · External reference
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
10.3389/fimmu.2021.721830 · 2021 · External reference
China approves world’s first oncolytic virus therapy for cancer treatment
10.1093/jnci/djj111 · 2006 · External reference
CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer
10.1158/1078-0432.ccr-05-1059 · 2006 · External reference
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
10.1038/sj.onc.1203251 · 2000 · External reference
Viruses in cancer treatment
10.1007/s12094-012-0951-7 · 2013 · External reference
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
10.1371/journal.pone.0002409 · 2008 · External reference
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
10.1128/jvi.77.11.6305-6313.2003 · 2003 · External reference
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
10.1086/509258 · 2006 · External reference
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
10.1086/587993 · 2008 · External reference
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
10.1016/s0140-6736(08)61592-5 · 2008 · External reference
Adenovirus serotype 5 hexon mediates liver gene transfer
10.1016/j.cell.2008.01.016 · 2008 · External reference
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
10.1128/jvi.02696-06 · 2007 · External reference
Generation and screening of a large collection of novel simian Adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans
10.1126/scitranslmed.3002925 · 2012 · External reference
A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
10.1371/journal.pone.0040385 · 2012 · External reference
A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting
External reference
Immunostimulatory Profile of Cancer Cell Death by the AdV-Lumc007-Derived Oncolytic Virus ‘GoraVir’ in Cultured Pancreatic Cancer Cells
10.3390/v15020283 · 2023 · External reference
Preclinical evaluation of the gorilla-derived HAdV‐B AdV‐lumc007 oncolytic adenovirus ‘GoraVir’ for the treatment of pancreatic ductal adenocarcinoma
10.1002/1878-0261.13561 · 2024 · External reference
A novel oncolytic adenovirus based on simian adenovirus serotype 24
10.18632/oncotarget.15845 · 2017 · External reference
Comparative Analysis of the Magnitude, Quality, Phenotype and Protective Capacity of SIV Gag-Specific CD8 + T Cells Following Human-, Simian- and Chimpanzee-Derived Recombinant Adenoviral Vector Immunisation
2013 · External reference
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
10.1038/nm0697-639 · 1997 · External reference
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
10.1038/mt.2009.262 · 2010 · External reference
Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation
10.3389/fmolb.2022.1039324 · 2022 · External reference
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
2024 · External reference
Targeting HER3 for cancer treatment: a new horizon for an old target
10.1016/j.esmoop.2023.100790 · 2023 · External reference
HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors
10.1016/j.pccm.2022.12.001 · 2023 · External reference
HER3 in cancer: from the bench to the bedside
2022 · External reference
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
10.1593/tlo.13475 · 2013 · External reference
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
10.1038/onc.2011.322 · 2012 · External reference
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
10.1016/j.jconrel.2018.03.016 · 2018 · External reference
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
10.1038/s41420-023-01692-8 · 2023 · External reference
EV20–sss–vc/MMAF, an HER–3 targeting antibody–drug conjugate displays antitumor activity in liver cancer
10.3892/or.2020.7893 · 2021 · External reference
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
10.3390/pharmaceutics13040483 · 2021 · External reference
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
10.18632/oncotarget.20728 · 2017 · External reference
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
10.1038/s41419-022-04701-3 · 2022 · External reference
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
10.1158/1535-7163.mct-15-0819 · 2016 · External reference
Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications
10.1128/jvi.79.20.12635-12642.2005 · 2005 · External reference
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX
10.1016/j.virusres.2018.08.012 · 2018 · External reference
Use of a Chimeric Adenovirus Vector Enhances BMP2 Production and Bone Formation
10.1089/104303402760128568 · 2002 · External reference
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
10.1038/gt.2010.17 · 2010 · External reference
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate
10.1016/j.jconrel.2024.08.009 · 2024 · External reference
Use of a chimeric adenovirus vector enhances BMP2 production and bone formation
10.1089/104303402760128568 · 2002 · External reference
Unresolved reference
2011 · External reference
Unresolved reference
2004 · External reference
Downregulation of human CD46 by adenovirus serotype 35 vectors
10.1038/sj.gt.3302946 · 2007 · External reference
Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
10.1158/1078-0432.ccr-14-2213 · 2015 · External reference
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients
10.1093/neuros/nyx507 · 2018 · External reference
Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1
10.1016/j.virol.2012.05.028 · 2012 · External reference
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration
10.36401/jipo-25-18 · 2025 · External reference
Unresolved reference
2012 · External reference
Substitution of Adenovirus Serotype 3 Hexon onto a Serotype 5 Oncolytic Adenovirus Reduces Factor X Binding, Decreases Liver Tropism, and Improves Antitumor Efficacy
10.1158/1535-7163.mct-10-0332 · 2010 · External reference
Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses Following Intravenous Delivery
10.1038/mt.2012.162 · 2012 · External reference
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
10.1136/jitc-2021-003255 · 2022 · External reference
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
10.1080/2162402x.2015.1105429 · 2015 · External reference
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
10.1016/j.ymthe.2021.04.022 · 2021 · External reference
Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates
10.1089/hum.2021.216 · 2022 · External reference
Packaging capacity and stability of human adenovirus type 5 vectors
10.1128/jvi.67.10.5911-5921.1993 · 1993 · External reference
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
10.1002/1878-0261.13453 · 2023 · External reference
The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60
10.1038/cddis.2011.99 · 2011 · External reference
Fiber-modified adenovirus for central nervous system Parkinson’s disease gene therapy
10.3390/v6083293 · 2014 · External reference
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
10.1002/1878-0261.13453 · ExternalCitation · doi-reference
Preclinical evaluation of the gorilla-derived HAdV‐B AdV‐lumc007 oncolytic adenovirus ‘GoraVir’ for the treatment of pancreatic ductal adenocarcinoma
10.1002/1878-0261.13561 · ExternalCitation · doi-reference
Viruses in cancer treatment
10.1007/s12094-012-0951-7 · ExternalCitation · doi-reference
Adenovirus serotype 5 hexon mediates liver gene transfer
10.1016/j.cell.2008.01.016 · ExternalCitation · doi-reference
The advent of oncolytic virotherapy in oncology: The Rigvir® story
10.1016/j.ejphar.2018.08.042 · ExternalCitation · doi-reference
Targeting HER3 for cancer treatment: a new horizon for an old target
10.1016/j.esmoop.2023.100790 · ExternalCitation · doi-reference
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
10.1016/j.jconrel.2018.03.016 · ExternalCitation · doi-reference
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate
10.1016/j.jconrel.2024.08.009 · ExternalCitation · doi-reference
HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors
10.1016/j.pccm.2022.12.001 · ExternalCitation · doi-reference
Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1
10.1016/j.virol.2012.05.028 · ExternalCitation · doi-reference
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX
10.1016/j.virusres.2018.08.012 · ExternalCitation · doi-reference
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
10.1016/j.ymthe.2021.04.022 · ExternalCitation · doi-reference
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
10.1016/s0140-6736(08)61592-5 · ExternalCitation · doi-reference
The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60
10.1038/cddis.2011.99 · ExternalCitation · doi-reference
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
10.1038/gt.2010.17 · ExternalCitation · doi-reference
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
10.1038/mt.2009.262 · ExternalCitation · doi-reference
Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses Following Intravenous Delivery
10.1038/mt.2012.162 · ExternalCitation · doi-reference
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
10.1038/nm0697-639 · ExternalCitation · doi-reference
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
10.1038/onc.2011.322 · ExternalCitation · doi-reference
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
10.1038/s41419-022-04701-3 · ExternalCitation · doi-reference
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
10.1038/s41420-023-01692-8 · ExternalCitation · doi-reference
Downregulation of human CD46 by adenovirus serotype 35 vectors
10.1038/sj.gt.3302946 · ExternalCitation · doi-reference
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
10.1038/sj.onc.1203251 · ExternalCitation · doi-reference
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
10.1080/2162402x.2015.1105429 · ExternalCitation · doi-reference
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
10.1086/509258 · ExternalCitation · doi-reference
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
10.1086/587993 · ExternalCitation · doi-reference
Use of a chimeric adenovirus vector enhances BMP2 production and bone formation
10.1089/104303402760128568 · ExternalCitation · doi-reference
Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates
10.1089/hum.2021.216 · ExternalCitation · doi-reference
China approves world’s first oncolytic virus therapy for cancer treatment
10.1093/jnci/djj111 · ExternalCitation · doi-reference
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients
10.1093/neuros/nyx507 · ExternalCitation · doi-reference
Generation and screening of a large collection of novel simian Adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans
10.1126/scitranslmed.3002925 · ExternalCitation · doi-reference
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
10.1128/jvi.02696-06 · ExternalCitation · doi-reference
Packaging capacity and stability of human adenovirus type 5 vectors
10.1128/jvi.67.10.5911-5921.1993 · ExternalCitation · doi-reference
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
10.1128/jvi.77.11.6305-6313.2003 · ExternalCitation · doi-reference
Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications
10.1128/jvi.79.20.12635-12642.2005 · ExternalCitation · doi-reference
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
10.1136/jitc-2021-003255 · ExternalCitation · doi-reference
CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer
10.1158/1078-0432.ccr-05-1059 · ExternalCitation · doi-reference
Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
10.1158/1078-0432.ccr-14-2213 · ExternalCitation · doi-reference
Substitution of Adenovirus Serotype 3 Hexon onto a Serotype 5 Oncolytic Adenovirus Reduces Factor X Binding, Decreases Liver Tropism, and Improves Antitumor Efficacy
10.1158/1535-7163.mct-10-0332 · ExternalCitation · doi-reference
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
10.1158/1535-7163.mct-15-0819 · ExternalCitation · doi-reference
Oncolytic viruses as therapeutic cancer vaccines
10.1186/1476-4598-12-103 · ExternalCitation · doi-reference
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
10.1245/s10434-018-6803-0 · ExternalCitation · doi-reference
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
10.1371/journal.pone.0002409 · ExternalCitation · doi-reference
A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
10.1371/journal.pone.0040385 · ExternalCitation · doi-reference
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
10.1593/tlo.13475 · ExternalCitation · doi-reference
A novel oncolytic adenovirus based on simian adenovirus serotype 24
10.18632/oncotarget.15845 · ExternalCitation · doi-reference
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
10.18632/oncotarget.20728 · ExternalCitation · doi-reference
Clinical Trials with Oncolytic Adenovirus in China
10.2174/156800907780058817 · ExternalCitation · doi-reference
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
10.3389/fimmu.2021.721830 · ExternalCitation · doi-reference
Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation
10.3389/fmolb.2022.1039324 · ExternalCitation · doi-reference
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
10.3390/pharmaceutics13040483 · ExternalCitation · doi-reference
Immunostimulatory Profile of Cancer Cell Death by the AdV-Lumc007-Derived Oncolytic Virus ‘GoraVir’ in Cultured Pancreatic Cancer Cells
10.3390/v15020283 · ExternalCitation · doi-reference
Fiber-modified adenovirus for central nervous system Parkinson’s disease gene therapy
10.3390/v6083293 · ExternalCitation · doi-reference
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration
10.36401/jipo-25-18 · ExternalCitation · doi-reference
EV20–sss–vc/MMAF, an HER–3 targeting antibody–drug conjugate displays antitumor activity in liver cancer
10.3892/or.2020.7893 · ExternalCitation · doi-reference
